PT  - JOURNAL ARTICLE
AU  - Lake, Douglas F.
AU  - Roeder, Alexa J.
AU  - Gonzalez-Moa, Maria J.
AU  - Koehler, Megan
AU  - Kaleta, Erin
AU  - Jasbi, Paniz
AU  - Vanderhoof, John
AU  - McKechnie, Davis
AU  - Forman, Jack
AU  - Edwards, Baylee
AU  - Seit-Nebi, Alim
AU  - Svarovsky, Sergei
TI  - Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders
AID  - 10.1101/2021.11.30.21266716
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.30.21266716
4099  - http://medrxiv.org/content/early/2021/12/02/2021.11.30.21266716.short
4100  - http://medrxiv.org/content/early/2021/12/02/2021.11.30.21266716.full
AB  - Objective To determine if poor responders to COVID-19 RNA vaccines (<50% neutralisation) after two doses would remain poor responders, or if a third dose could elicit high levels of NAbs.Design Clinical follow-up studySetting Academic and medical institutions in USAParticipants 269 healthy individuals ranging in age from 19 to 80 (Average age = 51; 165 females and 104 males) who received either BNT162b2 (Pfizer) or mRNA1273 (Moderna) vaccines.Main Outcome Measures NAb levels were measured: i) 2-4 weeks after a second vaccine dose, ii) 2-4 months after the second dose, iii) within 1-2 weeks prior to a third dose and iv) 2-4 weeks after a third RNA vaccine dose.Results In 269 study participants, percent neutralisation ranged from 0% to 99% 2-4 weeks after a second vaccine dose. The majority of vaccine recipients (154/269, 57%) demonstrated NAb levels at ≥75% 2-4 weeks after their second dose. Our study also revealed that 25% of vaccine recipients did not neutralise above 50% (Median neutralisation = 21%, titers <1:80) within a month after their second dose. We called these individuals “vaccine poor responders” (VPRs). Twenty-three VPRs ranging in age from 31 to 79 (10 males, 13 females, average age = 62.5) independently obtained a third dose of either BNT162b2 or mRNA-1273 vaccine 1-8 months (average = 5 months) after their second dose. Within a month after their third dose, poor responders showed an average 20-fold increase in NAb levels (range 46%-99%).Conclusions The results suggest that poor responders are not permanently poor responders; they can generate high NAb levels with an additional vaccine dose–independent of mRNA vaccine manufacturer. Previous reports indicate that NAb levels decline much more rapidly than clinical protection from hospitalisation and disease, but that does not account for vaccine recipients who never generated high levels of NAbs after two doses. It is possible that poor responders are a source of breakthrough infections. Although it is not known what levels of NAbs protect from infection or disease, many vaccine recipients in high-risk professions may wish to keep peripheral NAb levels high, limiting infection, asymptomatic viral replication, and potential transmission.Competing Interest StatementDFL and SS are co-founders of Sapphire, the research division of AXIM Biotechnologies. SS, MGM, and AS-N are employed by AXIM. All other authors have no competing interestsFunding StatementThis study was partially funded by Axim Biotech, San Diego, CAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Arizona State University Internal Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll de-identified raw data corresponding to results shown as part of the study demonstrated in this manuscript can be made available upon request to corresponding author.